Virtual Library
Start Your Search
Naziye Ak
Author of
-
+
EP1.15 - Thymoma/Other Thoracic Malignancies (ID 205)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Thymoma/Other Thoracic Malignancies
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.15-11 - Outcomes of Thymoma and Determinants of Survival: 16 Years Experience of a Tertiary Cancer Center (Now Available) (ID 1065)
08:00 - 18:00 | Author(s): Naziye Ak
- Abstract
Background
We aimed with this study to explore the demographics and clinical outcome of patients with thymoma.
Method
A total of 203 patients with thymoma (Masaoka stage II-IV) treated from 2002-2018 were included in this retrospective analysis. IBM-SPSS statistical software version 20 for Windows (IBM, NY) was used for analysis. Survival analysis were estimated by the Kaplan–Meier method and compared by the log-rank test. p<0.05 was considered statistically significant. Cox-regression tests used for multivariate analysis.
Result
Male:female ratio was 105:98 with median age 49 years (Range 11-77). At presentation, patients with stage II, III and IV disease were 90, 67 and 45, respectively. A total of 123 patients(60,6%) had myasthenia gravis, and 56,1% of these patients had presented with myasthenia related symptoms. Majority of the patients were operated with sternotomy(n=103), and mean hospital stay was 8,34 days (Table 1). A total of 76 patients had received adjuvant radiotherapy, and 31 patients and 35 patients had received adjuvant and neoadjuvant chemotherapy, respectively. At mean follow-up of 218,6 months(95%CI:201,8-235,3), 5-year and 10-year OS rates were 93,8% and 89,2%. 30 patients had recurrence after surgery, and 5-year and 10 year DFS rates were 76,5% and 68,3%. Masaoka-Koga stage(p<0.0001), postoperative hospital stay more than 10 days(p=0,004) and needing neoadjuvant chemotherapy(p=0,003) were significant effects on DFS. Among patients who had given neoadjuvant chemotherapy, comparing cisplatin with etoposide or doxorubicin based combinations did not change DFS(p=0,34) or OS (p=0,48). Adjuvant radiotherapy and chemotherapy also have no survival effect on DFS and OS. On univariate analysis, age(p=0.013), Masaoka-Koga stage(p=0.001), postoperative hospital stay more than 10 days(p=0,006) and having recurrence(p=0,013) were significant effects on OS. Stage (p=0,001) and age (p=0.007) retained its prognostic significance on multivariate analysis (Table 2).
Table1: Patient demographics and summary of the treatment approachs. Age n = 203
<=50
>50
111 (% 54,7)
92 (% 45,3)
Gender n = 203
Male
Female
105 (% 51,7)
98 (% 48,3)
Myasthenia Gravis n = 203
Yes
No
123 (% 60,6)
80 (% 39,4)
Acetylcholine Receptors n=123
Yes
No
113 (% 91,87)
10 (% 8,13)
Masaoka Stage of Thymoma
n = 202
II
III
IV
Unknown
90 (% 44,3)
67 (% 33)
45 (% 22,2)
1 (% 0,5)
Pathology n = 203
Type A
Type AB
Type B1
Type B2
Type B3
Mixed
Micronodular Thymoma
Unknown
15 (% 7,4)
20 (% 9,9)
40 (% 19,7)
67 (% 33,0)
32 (% 15,8)
25 (% 12,3)
1 (% 0,5)
3 (% 1,5)
Surgery type
VATS (Thoracoscopic)
Sternotomy
Thoracotomy
RATS
Inoperable
54 (% 26,6)
103 (% 50,7)
37 (% 18,2)
5 (% 2,5)
4 (%2)
Treatment Modality
Neoadjuvant Chemotherapy
Adjuvant Chemotherapy
Adjuvant Radiotherapy
35 (% 17,6)
31 (% 15,6)
76 (% 38,2)
Table 2: Five-year overall survival and recurrence-free survival estimates in patient subgroups 5-Year Survival Rate
OS
P
RFS
P
Age
≤50
%96,6 +/- 1,9
0,013
%77,8 +/- 4,5
0,510
>50
%84,2 +/- 4,7
%75 +/- 5,4
Gender
Male
%91,5 +/- 3,4
0,852
%76,5 +/- 5
0,687
Female
%90,9 +/- 3,3
%76,5 +/- 4,9
Masaoka stage
2
%96 +/- 2,3
0,001
%93,1 +/- 3
<0,001
3
%88,4 +/- 5
%77,8 +/- 6,4
4
%85,4 +/- 6,2
%42,1 +/- 8,8
Myasthenia Gravis
Yes
%93,1 +/- 2,6
0,648
%80 +/- 4
0,358
No
%87,3 +/- 5
%69,4 +/- 6,7
Diagnosed before 2008
Yes
%97,3 +/- 2,7
0,544
%80 +/- 6,8
0,247
No
%89,1 +/- 2,8
%75,4 +/- 4,1
Chemotherapy
No
Neoadjuvant
Adjuvant
%93 +/- 2,4
%86,9 +/- 7,2 %75 +/- 15,3
0,74
%86,4 +/- 3,2
%47,7 +/- 10
%21,8 +/- 13,4
<0,001
Radiotherapy Type
No
Neoadjuvant
Adjuvant
%90,3 +/- 3,3
%50 +/- 3,5 %93,5 +/- 3,2
0,588
%79,6 +/- 4,5
-
%74,9 +/- 5,5
0,436
Time of initiation of adjuvant therapy
Early
Late
%90,9 +/- 8,7
%89,1 +/- 6,1
0,867
%65,3 +/- 14,3
%72,8 +/- 8,5
0,853
Pathology Type
Type A
Type AB
Type B1
Type B2
Type B3
Mixed Hystology
%88,9 +/- 10
%100
%91,8 +/- 4,5
%93,2 +/- 3,9
%84,9 +/- 8,5
%85 +/- 7,7
0,506
%83,6 +/- 10,3
%87,1 +/- 8,6
%77,4+/- 7,1
%76,7 +/- 6,3
%77,8 +/- 9,3
%57,2 +/- 11,7
0,538
Hospitalisation Days
<10 days
%95,7 +/- 1,9
0,006
%87,1 +/- 3,1
0,004
>=10days
%78,9 +/- 7,2
%56,9 +/- 8,9
Recurrence
Yes
%88,9 +/- 6
0,013
NA
-
No
%91,7 +/- 2,6
NA
Masaoka-Koga clinical stage and age are the important prognostic factors predicting OS. Postoperative hospital stay is related to DFS and OS.
-
+
P2.17 - Treatment of Early Stage/Localized Disease (ID 189)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Treatment of Early Stage/Localized Disease
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.17-23 - The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study (Now Available) (ID 2301)
10:15 - 18:15 | Author(s): Naziye Ak
- Abstract
Background
Adjuvant chemotherapy is accepted as a standard treatment for suitable patients who have undergone surgery for T2N0 non-small cell lung cancer with tumors larger than 4 cm. Despite similar relapse rates, the benefit of adjuvant chemotherapy for smaller tumors with high risk features is not clear. In this retrospective analysis our aim was to evaluate the prognostic impact of adjuvant platin-based chemotherapy in high-risk stage 1 NSCLC patients.
Method
This cooperative group study included 250 NSCLC patients who underwent curative surgery for stage 1 NSCLC with tumor size 2-4 cm and adverse prognostic factors consisting of visceral pleural invasion(VPI), lympho-vascular invasion(LVI), high grade, presence of solid-micropapillary(SMP) components or STAS. Records of patients were analyzed to investigate the prognostic impact of adjuvant chemotherapy in this cohort. DFS was defined as the time from surgery to the last follow-up, until relapse or death, CSS;time from surgery to death related to cancer or last known contact, OS;time from diagnosis to death or last known contact. Statistical analysis was performed using SPSS 20.0 software(SPSSInc,Chicago,USA).
Result
Median age at presentation was 63 years (range 18-90). The mean tumor size was 29.4 ± 7.4 mm. The frequency of patients with specified risk factors were: VPI: n: 92 (36.8%); LVI: n: 91 (36.4%); Grade 3:n: 49 (19,6%); SMP:n: 76 (30.4%); STAS:n: 15 (6%). A total of 51 patients had received adjuvant platin-based chemotherapy. There were significantly more patients who received chemotherapy in the younger age group (<65 ears old, ≥65 years old) and those with larger tumors (2 – 3 cm, 3 – 4 cm).
During a median follow-up period of 91.8 months; 79 patients(31.6%) experienced recurrence, 62 patients(24.8%) have died, 144 patients(57.6%) were alive without disease and 24 patients (9.6%) were alive with disease.
5-year and 10-year OS rates were 72.7%(± 3,5) and 46.8%(± 8), respectively. There was a significant improvement in DFS with adjuvant chemotherapy, especially in groups with VPI (93.3% vs 53.6%, p:0.016) and SMP (92.3% vs 57.3%, p:0.03). There was also a non-significant trend for improved CSS and OS among patients who received CT.
Table 1. Effects of chemothrapy on survival. Chemotherapy Group
Non - treatment Group
P Value DFS 12/51 NE % 74.9 ± 6.3 81/190 71.1 months % 54 ± 4.2 0,032* CSS 4/49 NE % 89 ± 5 41/179 91.8 months % 76.9 ± 3.8 0,078 OS 10/49 NE %77.4 ± 6.4 51/179 88.9 months % 72.1 ± 4 0,541 *All values are stratified, respecting to significant confounding factors such as age, gender and tumor size.
Conclusion
Adjuvant platin-based chemotherapy should be considered for this subset of patients having high grade tumors, or those with VPI, LVI or solid-micropapillary components. Prospective, randomized trials incorporating clinical and molecular risk factors are required to clarify the role of adjuvant chemotherapy for stage 1 NSCLC patients.